Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase III trial comparing early treatment with fludarabine/cyclophosphamide + rituximab versus deferred treatment in untreated Binet stage A patients with CLL [chronic lymphocytic leukaemia] and high risk of progression

Next Previous
X
Search
Trial Profile

Randomized phase III trial comparing early treatment with fludarabine/cyclophosphamide + rituximab versus deferred treatment in untreated Binet stage A patients with CLL [chronic lymphocytic leukaemia] and high risk of progression

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms CLL7

    • Most Recent Events

    • 31 Jul 2022 This trial has been discontinued in Czechia, according to European Clinical Trials Database record.
    • 08 Dec 2020 Results of pooled analysis (CLL7, CLL8, CLL10, CLL11 and CLL2M)presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 16 Aug 2006 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top